Fennec reports Q4 EPS (17c), consensus 4c

Reports Q4 revenue $13.78M, consensus $14.73M. “Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec (FENC) into its next chapter of growth. We delivered record net product sales, achieved significant growth within our Fennec Hears program, and advanced independent clinical evidence generation for Pedmark – all while driving quarter-over-quarter growth in every quarter in 2025. These results demonstrate increasing Pedmark adoption across key accounts and patient segments, effective field execution, and sustained progress across the organization,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “Concurrently, we strengthened our financial position through prudent operating decisions and strategic financial initiatives, including the closing of public and private offerings and the completion of full debt redemption.”